NasdaqGS - Nasdaq Real Time Price USD

ImmunityBio, Inc. (IBRX)

2.8217
-0.0183
(-0.64%)
As of 1:14:34 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IBRX

Recent News: IBRX

View More
Exploring 3 High Growth Tech Stocks In The US Market

Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St. 4 days ago
Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00

Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00
Simply Wall St. 5 days ago
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
Business Wire 7 days ago
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
Business Wire 14 days ago
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
Business Wire 21 days ago
Astera Labs And Two More Top Growth Companies With Strong Insider Ownership

Astera Labs And Two More Top Growth Companies With Strong Insider Ownership
Simply Wall St. 24 days ago
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Business Wire 27 days ago
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
Business Wire last month
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple
Insider Monkey last month
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
Business Wire last month
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
Business Wire last month
View More

Related Tickers

IOVA Iovance Biotherapeutics, Inc.
1.7750
+6.93%
 
CTMX CytomX Therapeutics, Inc.
2.1350
+5.17%
 
SMMT Summit Therapeutics Inc.
23.41
-1.93%
 
BLUE bluebird bio, Inc.
4.9750
+0.10%
 
SGMO Sangamo Therapeutics, Inc.
0.4888
+3.99%
 
ARDX Ardelyx, Inc.
3.9250
+1.16%
 
VKTX Viking Therapeutics, Inc.
27.31
-3.96%
 
TGTX TG Therapeutics, Inc.
34.25
-0.32%
 
ALT Altimmune, Inc.
5.48
-1.79%
 
CADL Candel Therapeutics, Inc.
5.35
0.00%